AstraZeneca PLC (NASDAQ:AZN) is one of the best defensive stocks to buy, according to Steve Cohen. On September 7, the company announced positive clinical trial results involving Tagrisso in combination with pemetrexed and platinum-based chemotherapy. AstraZeneca PLC (AZN) Receives Tagrisso Boost in Lung Cancer Trials Pixabay/Public Domain The trial results showed that the combination extended the lives of some lung cancer patients by a median of 47.5 months. It is the longest survival benefit ever reco ...